Sideinnhold
A -
B -
C -
D -
E -
F -
G -
H -
I -
J -
K -
L -
M -
N -
O -
P -
Q -
R -
S -
T -
U -
V -
X -
Y -
Z
| Ocrevus (S) | ocrelizumab | PPMS | 2018 |
|---|
| Ocrevus (S) | ocrelizumab | RMS | 2018 |
|---|
| olmesartan | Hypertensjon | 2005 |
|---|
|
Olumiant (S) | Baricitinib | Revmatoid artritt | 2017 |
|---|
| Olysio | simeprevir | Hepatitt C | 2015 |
|---|
| Omnitrope | somatropin | Hypopituitarisme | 2013 |
|---|
| indakaterol | KOLS | 2010 |
|---|
| saksagliptin | Diabetes type 2 | 2010 |
|---|
| Onivyde (S) | liposomal irinotekan | Pankreaskreft | 2017 |
|---|
| Opdivo (S) | nivolumab | Blærekreft | 2018 |
|---|
|
Opdivo (S) | nivolumab | Malignt melanom | 2015 |
|---|
|
Opdivo (S) | nivolumab | Malignt melanom | 2017 |
|---|
| Opdivo (S) | nivolumab | Melanom adjuvant | 2019 |
|---|
|
Opdivo (S) | nivolumab | Lungekreft (ikke- plateepitelkarsinom) | 2016 |
|---|
| Opdivo (S) | nivolumab | Lungekreft (plateepitelkarsinom) | 2016 |
|---|
|
Opdivo (S) | nivolumab | Nyrekreft | 2016 |
|---|
| Opdivo (S) | nivolumab | Hodgkins lymfom | 2017 |
|---|
|
Opdivo (S) | nivolumab | Hode-halskreft | 2017 |
|---|
| Orale legemidler | |
Verdien av fordelen av oral administrasjon | 2013 |
|---|
| Ozempic | semaglutid | Diabetes type 2 | 2019 |
|---|
| Otezla (S) | apremilast | Psoriasis | 2016 |
|---|
| Otezla (S) | apremilast | Psoriasisartritt | 2016 |
|---|
| Oviderm | propylenglykol | Atopisk dermatitt | 2018 |
|---|
